

30th July, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Outcome of the Board Meeting
BSE Code: 531210

The Meeting of Board of Directors was held on Saturday, 30th July, 2022 at 03:30 p.m. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-Audited Financial Results for the quarter ended 30th June, 2022 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Statutory Auditors have carried out "Limited Review" of the above results. Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June, 2022.
2. The Board approved Director's Report for the year ended 31st March, 2022.
3. The Board also approved Management Discussion Report, Corporate Governance Report, CEO's certification & other documents for the year ended 31st March, 2022.
4. The Board took note of Secretarial Audit Report issued by M/s. Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2022.
5. The Board approved the appointment of M/s. Vora & Associates, Chartered Accountant as Statutory Auditor of the Company for the second term of 5 years and recommended the same for approval of the members in the forthcoming Annual General Meeting.
6. The Board discussed and approved appointment of Mr. N.K.Menon as Whole time Director and CEO for further term of 3 years subject to approval of members in the forthcoming Annual General Meeting.
7. The Board discussed and finalized the date, time and mode of 36th Annual General Meeting of the Company on **Friday, 30th September, 2022, at 2.30 P. M.** through video conference or other audio-visuals means and also approved the draft notice of forthcoming Annual General Meeting of the Company.

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



8. The Board also approved and finalized that the Register of Members will remain closed for the purpose of 36th Annual General Meeting of the Company from **23rd September, 2022, to 30th September, 2022** (both days inclusive). Notice relating to Book Closure is enclosed separately.
9. Further pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed **23rd September, 2022** as the Cut-Off date for the purpose of determining the eligible shareholders (holding shares either in physical form or in dematerialized form) to cast their votes electronically between **27th September, 2022** (9:30 A.M. IST) to **29th September, 2022** (5:00 P.M. IST).
10. The Board also considered and approved appointment of M/s. Sanjay Dholakia & Associates, Practising Company Secretaries as the Secretarial Auditor for the financial year ended 31st March, 2023.

The Board Meeting commenced at 3:30 p.m. and concluded at 5.00 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L.S.

Director & Company Secretary

DIN : 00825886



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

91-99305 75933
022-2200 5933 - 2200 5934
www.cavoras.com
office@cavoras.com
cavoras@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter ended 30th June, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)



UDIN: 22140371ANXOLR2209
PLACE: MUMBAI
DATED: July 30, 2022

COLINZ LABORATORIES LIMITED.
Colinz

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2022

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited		Audited	
		Quarter ended		Quarter ended	YEAR ENDED
		30-Jun-22	30-Jun-21	31-Mar-22	31-Mar-22
1	(a) Revenue from Operation	183.81	185.04	158.20	697.42
3	(b) Other Income	4.12	4.14	7.07	17.08
3	Total Income from Operation	187.93	189.18	165.27	714.50
4	Expenses				
	(a) Cost Of Material Consumed	18.41	16.66	16.59	60.13
	(b) Purchase of Stock in Trade	53.43	32.67	31.67	136.92
	(c) Change in Inventories Of Finished Goods and Work in Progress and Stock in Trade	(14.78)	10.55	8.06	32.80
	(d) Employee Benefit Expenses	78.74	73.83	72.13	290.30
	(e) Finance Cost	1.23	2.01	1.27	7.55
	(f) Depreciation & Amortisation Expenses	3.22	4.98	5.00	20.11
	(g) Other Expenses	33.40	37.28	18.15	118.66
	Total Expenses	173.65	177.98	152.87	666.47
5	Profit / (Loss) Before exceptional items and tax (3-4)	14.28	11.20	12.40	48.03
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5-6)	14.28	11.20	12.40	48.03
8	Tax Expenses (Provision for Taxation) Current tax				
	i) Current Tax	3.25	2.75	5.64	14.35
	ii) Deferred Tax	-	-	(0.97)	(0.97)
	iii) Tax for earlier years	-	-	0.72	0.72
9	Profit / (Loss) for the period from continuing operations(7-8)	11.03	8.45	7.01	33.93
10	Profit / (Loss) for the period	11.03	8.45	7.01	33.93
11	Other Comprehensive Income (Net of Tax)				
	A) Item that will not be reclassified to Profit or Loss Account				
	i) Change in fair value of investment in Equity Instruments	(6.05)	4.66	(3.21)	5.68
12	Total Comprehensive Income for the period (10+11) Comprising Profit / (Loss) and Other Comprehensive Income for the Period	4.98	13.11	3.80	39.61
13	Earning per equity share (for Continuing operation) (In Rs.)				
	i) Basic	0.44	0.18	0.15	0.74
	ii) Diluted	0.44	0.18	0.15	0.74


Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078, INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com


Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006




NOTES TO THE FINANCIAL RESULTS :-


- 1) The above financial results for the Quarter Ended 30.06.2022 have been prepared by the Company in accordance with Indian Accounting Standards(Ind AS) prescribed under section 133 of the Companies Act,2013 read with relevent Rules issued thereunder and in item of Regulation 33 of SEBI (LODR) Regulation,2015(as amended) and were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 30th July,2022.
- 2) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous figures have been regrouped/ rearranged , wherever necessary.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128


Dr. Mani L. S. (Din No : 00825886)
Director & Company Secretary



MUMBAI.
30th July,2022.



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006